Login
$IVVD
$0.55 +$0.01 (2.27%) After hours

$IVVD 8-K SEC Filings

Filed On Filing
16 Nov 2026 8-K: Results of Operations and Financial Condition

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

29 Sep 2026 8-K: Other Events

Invivyd Announces Positive Topline Results from LIBERTY Phase 3 Study Demonstrating VYD2311 Safety and Tolerability Superior to mRNA-based COVID-19 Vaccine; Announces Regulatory Submission Plans for VYD2311

01 Sep 2026 8-K: Departure/Election of Directors or Officers; Compensation; Other Events

This Employment Agreement (“Agreement”) is made between Invivyd, Inc., a Delaware corporation (the “Company”), and Marc Elia (“Executive”), this 30th day of August, 2026.

13 Aug 2026 8-K: Results of Operations and Financial Condition

Achieved Q2 2026 PEMGARDA® (pemivibart) net product revenue of $14.3 million, representing 21% growth versus Q2 2025 net product revenue of $11.8 million

24 Jul 2026 8-K: Notice of Delisting or Failure to Satisfy a Listing Rule

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

06 Jul 2026 8-K: Other Events

On July 6, 2026, Invivyd, Inc. issued a press release entitled “Invivyd Announces Receipt of Twelve Months’ Advanced Notice of Emergency Use Authorization (EUA) Termination for PEMGARDA® and Provides an Update on Next Steps with the U.S....

19 May 2026 8-K: Submission of Matters to a Vote of Security Holders

On May 19, 2026, Invivyd, Inc. (the “Company”) held its Annual Meeting of Stockholders (the “Annual Meeting”). The following is a summary of the matters voted on at the Annual Meeting and the final voting results as certified by the Comp...

14 May 2026 8-K: Results of Operations and Financial Condition; Other Events

Achieved Q1 2026 PEMGARDA® (pemivibart) net product revenue of $13.7 million, representing 22% growth versus Q1 2025 net product revenue of $11.3 million

09 Apr 2026 8-K: Other Events

Invivyd Announces REVOLUTION Program Progress and Advancement of Novel, Potential First- and Best-in-Class Measles Monoclonal Antibody Candidate VMS063 for Treatment and Prevention of Measles

05 Mar 2026 8-K: Results of Operations and Financial Condition; Other Events

Invivyd Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides Recent Business Highlights and DECLARATION Clinical Trial Updates

08 Jan 2026 8-K: Results of Operations and Financial Condition; Other Events

Preliminary Q4 2025 PEMGARDA® (pemivibart) net product revenue of $17.2 million, representing 25% growth year-over-year and 31% growth quarter-over-quarter

23 Dec 2025 8-K: Other Events

NEW HAVEN, Conn., Dec. 23, 2025 – Invivyd, Inc. (Nasdaq: IVVD) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for VYD2311, an investigational vaccine-alternative monoclonal antibody ca...

24 Nov 2025 8-K: Other Events

VBY329 is designed for the prevention of Respiratory Syncytial Virus (RSV) infections in newborns, infants, and children, and results from Invivyd’s proprietary antibody discovery technology platform

19 Nov 2025 8-K: Entry into a Material Definitive Agreement; Other Events

Pre-Funded Warrants to Purchase 6,000,000 Shares of Common Stock

06 Nov 2025 8-K: Results of Operations and Financial Condition; Other Events

PEMGARDA® (pemivibart) net product revenue of $13.1 million reported for Q3 2025, representing 41% growth year-over-year and 11% growth quarter-over-quarter

30 Oct 2025 8-K: Other Events

Life can only be understood backwards; but it must be lived forwards… KIERKEGAARD Invivyd 1 October 30, 2025 © 2025 Invivyd, Inc. All trademarks used in this presentation are the property of their respective owners.

06 Oct 2025 8-K: Other Events

Invivyd Announces U.S. IND Clearance and Alignment with U.S. FDA on Pivotal Clinical Program for VYD2311, a Vaccine-Alternative Antibody to Prevent COVID

24 Sep 2025 8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure +1 more

NEW HAVEN, Conn., Sept. 24, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (NASDAQ: IVVD) today announced the appointment of Paul B. Bolno, M.D., to its Board of Directors and as a member of the Compensation Committee. Dr. Bolno is the President...

22 Aug 2025 8-K: Entry into a Material Definitive Agreement; Other Events

Pre-Funded Warrants to Purchase 21,342,442 Shares of Common Stock

14 Aug 2025 8-K: Results of Operations and Financial Condition; Other Events

PEMGARDA® (pemivibart) net product revenue of $11.8 million reported for Q2 2025, representing 413% growth year-over-year

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support